MISSION STATEMENT: To prove that non-human intervention by an analytical chatbot is far superior to the other kind.
OVERVIEW: Our AI algorithm is an investment predictor that gathers data from 129 preset sources and presents the values as a SPM matrix number. The database tracks over 5215 individual stocks with each one carrying a "floating" SPM tag. The higher the value the greater the subjective probability of the collective data being accurate and culminating with the issuance of an auxiliary SPM tag.
$SOFI $10.24 bid. DAC (dollar average cost) $7.23 (4.4.24. CHANGE EXIT TO $16.00 FROM $12.00. REVIEW: SoFi previously announced agreement to expand its personal lending business with a $2 billion funding agreement with Fortress Investment Group. Simply put, SoFi will underwrite personal loans but then offload them. SoFi will miss out on the interest income, but it will reduce its balance sheet risk. CEO Anthony Noto commented in the press release, noting an intention to grow SoFi's fee-based revenue. Holding fewer loans on its books could affect how the market values SoFi stock. note: SPM tag claims it would add $5.00 to current stock price.
$OCS $16.31 bid. DAC (dollar average cost) $10.50 (11.10.23). EXIT $25.00 - Legacy Holding. OVERVIEW: Today announces the acceleration of patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in DME and expansion of the DIAMOND program committees with globally renowned retina experts. Substantial enrollment progress was achieved since the end of Q2 2024 through early October, with ~70% of patients enrolled in the Phase 3 DIAMOND-1 trial, and ~40% of patients enrolled in the Phase 3 DIAMOND-2 trial. The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consists of two (2) Phase 3, double-masked, randomized, multi-center trials which will evaluate the efficacy and safety of OCS-01 eye drops in patients with DME.
#SPMNOTE "Classic example of SPM tag identifying a significate anomaly." $ANRO $4.352 - $9.99. History ^^ $ANRO at $8.36 on 8.12.24 declared BUY/NEW LONG POSITION carried SPM 86.99 tag to $14.00 EXIT. ^^ $ANRO at $13.56 on 10.14.24 was SOLD/TAKE PROFIT on near EXIT ($14.00) because it failed the rating for tag enhance by dropping 475 bits.. note: Such major change foretold a significant devaluation may happen in the future. ^^ On October 23, 2024 ANRO announced its Phase IIb clinical trial of ALTO-100 for treating major depressive disorder (MDD) failed to meet its primary endpoint and the stock dropped over 10 points. Factor. ANRO is not an isolated case. No other AI algorithm or human intervention (other than stock manipulation i.e. insider trading) has or duplicated what has been expressed herein. Click SEARCH (magnifying glass) icon on our landing page to review the postings.
$SOFI $11.05 was carries a SPM 87.50 + tag (on average) and finally lost 256 bits. Our AI (GenAI) model "ordered" a SELL and TAKE PROFIT. That's what we did. History: SOFI on April 4, 2024 when added to the portfolio at $7.23 when 395 bit increase was recorded. At the time not one investment firm picked it a BUY --- the best was a neutral rating (downgraded to Neutral from Buy at Guggenheim). Meanwhile , SOFI issued "downside guidance for Q2, sees Q2 revs of $555-$565 mln vs. $584.21 mln SPM consensus. Guides for adjusted EBITDA of $115 to $125 million and Net Income of $5 to $10 million." Based on all the conventional data SOFI was a "dog-in-waiting," but our data heard a different noise.
Comments